PBLS logo

PBLS Parabilis Medicines, Inc.

NASDAQ · Biotechnology · Healthcare

$27.44
-0.18 (-0.67%)

Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

Market Cap: $3.39Bwww.parabilismed.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
50
6 mentions
—
60d
52
8 mentions
—
90d
50
11 mentions
—
news: 9 · rss: 2

Analyst Ratings

Avg price target$40+45.8%
Low $40Median $40High $40
Current Consensus

Revenue

$2.11M
$0.00$704.7K$1.41M$2.11M
Mar 2025Sep 2026

Analyst Estimates

FY2026
$-2.56
$-3.00–$-2.12
3 analysts
FY2027
$-1.82
$-1.98–$-1.66
3 analysts
FY2028
$-1.88
$-1.95–$-1.80
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Mathai Mammen
Sector
Healthcare
Industry
Biotechnology
Employees
145
Beta
5.03
Country
US
www.parabilismed.com